![conference banner](/images/conference-banner.jpeg)
Abstract
This review describes the role of nuclear receptors in the regulation of genes involved in cholesterol transport and synthetic modulators of these receptors. Increasing the efflux of cholesterol from peripheral cells, such as lipid-laden macrophages, through a process called reverse cholesterol transport (RCT) requires HDL. Increasing the circulating levels of HDL, as well as the efficiency of the RCT process, could result in a reduction in the development of coronary artery disease and atherosclerosis. Nuclear receptors of the RXR heterodimer family have recently been shown to regulate key genes involved in HDL metabolism and reverse cholesterol transport. These include the PPARs (peroxisome proliferator activated receptors), the LXR (liver X receptor) and the farnesoid X receptor (FXR). The synthesis of specific and potent ligands for these receptors has aided in ascertaining the physiological role of these receptors as lipid sensors and the potential therapeutic utility of modulators of these receptors in dyslipidemias and cardiovascular disease.
Keywords: atherosclerotic disease, low density lipoproteins (ldl), reverse cholesterol transport (rct), coronary artery disease, peroxisome proliferator activated receptor alpha, rexinoid x receptor (rxr), phospholipid, expression
Current Topics in Medicinal Chemistry
Title: Nuclear Receptors as Potential Targets for Modulating Reverse Cholesterol Transport
Volume: 5 Issue: 3
Author(s): Patricia D. Pelton, Mona Patel and Keith T. Demarest
Affiliation:
Keywords: atherosclerotic disease, low density lipoproteins (ldl), reverse cholesterol transport (rct), coronary artery disease, peroxisome proliferator activated receptor alpha, rexinoid x receptor (rxr), phospholipid, expression
Abstract: This review describes the role of nuclear receptors in the regulation of genes involved in cholesterol transport and synthetic modulators of these receptors. Increasing the efflux of cholesterol from peripheral cells, such as lipid-laden macrophages, through a process called reverse cholesterol transport (RCT) requires HDL. Increasing the circulating levels of HDL, as well as the efficiency of the RCT process, could result in a reduction in the development of coronary artery disease and atherosclerosis. Nuclear receptors of the RXR heterodimer family have recently been shown to regulate key genes involved in HDL metabolism and reverse cholesterol transport. These include the PPARs (peroxisome proliferator activated receptors), the LXR (liver X receptor) and the farnesoid X receptor (FXR). The synthesis of specific and potent ligands for these receptors has aided in ascertaining the physiological role of these receptors as lipid sensors and the potential therapeutic utility of modulators of these receptors in dyslipidemias and cardiovascular disease.
Export Options
About this article
Cite this article as:
Pelton D. Patricia, Patel Mona and Demarest T. Keith, Nuclear Receptors as Potential Targets for Modulating Reverse Cholesterol Transport, Current Topics in Medicinal Chemistry 2005; 5 (3) . https://dx.doi.org/10.2174/1568026053544588
DOI https://dx.doi.org/10.2174/1568026053544588 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Obstructive Sleep Apnea and Type 2 Diabetes: Dual Interaction
Current Respiratory Medicine Reviews The ACE2-Ang-(1-7)-Mas Axis and Cardioprotection
Current Cardiology Reviews New Challenges and Strategies for Cardiac Disease: Autophagy, mTOR, and AMP-activated Protein Kinase
Current Neurovascular Research Venom Peptide Modulators of the Immune System
Inflammation & Allergy - Drug Targets (Discontinued) ENaC Modulators and Renal Disease
Current Molecular Pharmacology On the Physiological Relevance of Muscarinic Acetylcholine Receptors in Alzheimers Disease
Current Medicinal Chemistry Polyphenols Effect on Circulating Lipids and Lipoproteins: From Biochemistry to Clinical Evidence
Current Pharmaceutical Design Kidney Injury Molcule-1 in Acute and Chronic Kidney Disease
Recent Patents on Biomarkers Bariatric Surgery and Rheumatic Diseases: A Literature Review
Reviews on Recent Clinical Trials The Role of NAD<sup>+</sup> in Myocardial Ischemia-induced Heart Failure in Sprague-dawley Rats and Beagles
Current Pharmaceutical Biotechnology PCSK9 A/G (rs505151) Gene Polymorphism and its Expression at the Molecular Level in Patients with Coronary Artery Disease
Current Pharmacogenomics and Personalized Medicine Subcellular Analysis of the Platelet Proteome
Current Proteomics Angiotensin Converting Enzyme Inhibitory Peptides Derived from Food Proteins: Biochemistry, Bioactivity and Production
Current Pharmaceutical Design The Proteomic Approach in the Development of Prognostic Biomarkers in Atherothrombosis
Recent Patents on Cardiovascular Drug Discovery Cyclophilin D-mediated Mitochondrial Permeability Transition Regulates Mitochondrial Function
Current Pharmaceutical Design Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Current Pharmaceutical Design Cardiovascular Diseases in Pregnancy - A Brief Overview
Current Cardiology Reviews SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry The Cost-Effectiveness of Palivizumab in the Prevention of Respiratory Syncytial Virus Bronchiolitis: A Systematic Review
Current Respiratory Medicine Reviews Short Term, Low Dose Simvastatin Pretreatment Alters Memory Immune Function Following Secondary Staphylococcus aureus Infection
Current Pharmaceutical Biotechnology